Cargando…
HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
SIMPLE SUMMARY: The human epidermal growth factor receptor 2 (HER2) became the first routinely targeted biomarker in the management of stomach cancers when the monoclonal antibody trastuzumab given with chemotherapy was shown to improve patient survival in 2010. Over the past decade, we have develop...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367333/ https://www.ncbi.nlm.nih.gov/pubmed/35954487 http://dx.doi.org/10.3390/cancers14153824 |